Lurasidone-d₈is intended for use as an internal standard for the quantification of lurasidone by GC- or LC-MS. Lurasidone is an atypical antipsychotic that binds to dopamine D₂, serotonin (5-HT) receptor subtypes 5-HT_2A, 5-HT_1A, and 5-HT₇, and α_2C-adrenergic receptors (K_is = 1.68, 2.03, 6.75, 0.495, and 10.8 nM, respectively).¹In vivo, pre-training administration of lurasidone (1 and 3 mg/kg) reverses impairment in step-through latency and passive avoidance in a foot shock test induced by MK-801 in rats. It reverses MK-801-induced learning impairment in the Morris water maze as well as reference and working memory impairment in the radial arm maze in rats.²Lurasidone also decreases immobility in the tail suspension and forced swim tests, indicating antidepressant-like activity in mice.³Formulations containing lurasidone have been used in the treatment of schizophrenia and mood disorders.

1.Ishiyama, T., Tokuda, K., Ishibashi, T., et al.Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance testEur. J. Pharmacol.572(2-3)160-170(2007) 2.Enomoto, T., Ishibashi, T., Tokuda, K., et al.Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in ratsBehav. Brain Res.186(2)197-207(2008) 3.Cates, L.N., Roberts, A.J., Huitron-Resendiz, S., et al.Effects of lurasidone in behavioral models of depression. Role of the 5-HT? receptor subtypeNeuropharmacology70211-217(2013)